Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Izencitinib (JNJ-8398) is an orally active and gut-selective JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 20,500 | |||
5 mg | 在庫あり | ¥ 49,000 | |||
10 mg | 在庫あり | ¥ 80,000 | |||
25 mg | 在庫あり | ¥ 159,500 | |||
50 mg | 在庫あり | ¥ 250,500 | |||
100 mg | 在庫あり | ¥ 411,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 54,000 |
説明 | Izencitinib (JNJ-8398) is an orally active and gut-selective JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease. |
ターゲット&IC50 | JAK3:9.5(pKi), JAK1:10.0(pKi), JAK2:8.8 (pKi) |
In vitro | Izencitinib ( TD-1473 ), as an effective inhibitor of JAK1, JAK2 and JAK3, can act on the human JAK kinase domain ( pKi values are 10.0,8.8 and 9.5, respectively )[1]. |
In vivo | Izencitinib ( TD-1473,1 mg / kg BID ) can be used in oxazolone-induced colitis in mice[1]. |
別名 | TD-1473, JNJ-8398 |
分子量 | 402.50 |
分子式 | C22H26N8 |
CAS No. | 2051918-33-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (74.53 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Izencitinib 2051918-33-1 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK TD-1473 JNJ-8398 Inhibitor inhibitor inhibit